TORONTO, ON--(Marketwired - April 23, 2014) - Easton Pharmaceuticals Inc. (OTC: EAPH) announces it has received a final draft of its Reg. A SEC document that is set to be filed with the Securities and Exchange Commission later this week.
Easton's Delaware attorney has submitted final changes of the filing to the company's board for review and comment. The company anticipates submitting the filing with the Securities and Exchange Commission sometime within the next few days or the end of this week. The Reg. A filing is being supported by its current finance partners who in the past 9 months have advanced Easton Pharmaceuticals with $1,000,000 in financing. Once filed with the SEC, the company should receive comments back, if any, within 10 to 20 days. The company's current financing partners have committed to move forward, have asked for an exclusive and believe they will be able to finance the full $5,000,000 over the next year.
The additional financings are required to fulfill most, if not all initiatives which includes purchasing majority control of its early stage cancer drug "Xilive," completing patent applications and to move towards initiating early stage clinical trials in certain select countries and jurisdictions. Funding is also required to start manufacturing, marketing and sales of its OTC "Viorra" product and its other OTC line of products which are all at different stages of development, as well as to move towards finalizing on its medical marijuana initiatives which have advanced.
Easton Pharmaceuticals believes its efforts in the medical marijuana industry may soon result in a positive development that will allow the company to enter the medical marijuana industry as a possible grower and seller of medical marijuana and other types of marijuana products, which will include future growth and expansion abilities. This may initially involve certain jurisdictions of the United States, Canada and possibly both with adequate financing.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors that owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues related towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company is also endeavoring to enter other potentially lucrative industries such as medical marijuana. The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals' product "VIORRA" is an over-the-counter, topical daily use product and aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder); the world market for these female conditions is conservatively estimated to be in the billions.
For More Information Visit:
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment could be classified as speculative and risky. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.